الفهرس 
COVID-19 over viewOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
The aim of the present work was to study the relation between COVID-19 vaccination and the skin manifestation among random sample of Egyptian people at age group from 18 years old and older people.
The study was conducted on 480 vaccinated people at age group between 18 years old and older people after exclude participants of exclusion criteria, this study was carried out between July 2021 and January 2022 in the outpatient clinic of Dermatology and Andrology, Menoufia University Hospital and the vaccination center in Egypt, after taking the approval of Dermatology and Andrology Department and Medical Ethics Committee No. (82021DERM1) 2021.
In this study, we used self-report Questionnaire translated to Arabic. Questionnaire consisted of 27 aspects that covered relations between COVID-19 vaccine and skin manifestations.
The results of this study showed that:
About 51.9% received Oxford- AstraZeneca vaccine,11% received Pfizer-BioNTech vaccine, 30.4 received Sinopharm vaccine, 5.4% received Sinopharm vaccine and 1.3% received Johnson‘s Janssen vaccine.
No significant difference between studied participants regards age and sex.
Pain at sit of vaccination, fever, nausea and vomiting are the most common manifestation after current vaccination.
About 85.4% had manifestations rather than skin manifestations including (tiredness, joint pain, headache, muscle pain, chills, fever and nausea and vomiting).
11.5 % had nausea and vomiting after vaccination.
10.8 % of participants had allergic manifestations to vaccine, 1.5 % had edema of mouth, lips, tongue.
After comparison between types of vaccine regarding allergic manifestations we found about 16.1 % of participants had allergic manifestations after Oxford-AstraZeneca vaccine, 3.8 % after Pfizer-BioNTech vaccine, while 6.8 % after Sinopharm vaccine.
As regards to edema of mouth, lips and tongue, 2.8 % of participants had edema after Oxford-AstraZeneca vaccine.
Skin manifestations after vaccination represent about 37.5 % of the participants which included 37.5 % of participants had itching or redness or edema at site of vaccination, 1.9 % had COVID toe manifestation, 1.5 % had Herpes simplex, 2.5 % had Pityriasis rosea, 1.3 % had clots, 5.2 % of participants had Herpes zoster 1 % had ALEP (Acute localized exanthematous pustulosis), 2.9 % had Acute urticarial, 1.5 % had Pruritis and 0.4 % had Erythema nodosum